Zimmer Biomet Cut to Neutral by BTIG BTIG cut Zimmer Biomet to Neutral on Mar 23, 2026 (Investing.com); industry growth is ~5.8% CAGR to 2030 (Grand View Research, 2024).

Zimmer Biomet Cut to Neutral by BTIG: BTIG cut Zimmer Biomet to Neutral on Mar 23, 2026 (Investing.com); industry growth is ~5.8% CAGR to 2030 (Grand View Research, 2024). 👈 Read full analysis #ZimmerBiomet #BTIG #Investing #Healthcare #MedicalDevices

NHS Scotland Device Safety release on Zimmer Biomet NexGen Knee replacement #NexGenKnee #NHSScotland #ZimmerBiomet #KneeReplacement

www.bbc.co.uk/news/article...

Zimmer Biomet raises annual profit forecast on lower tariff impact (Corrects to "Thursday" from "Wednesday" in paragraph 1) By Kamal Choudhury (Reuters) -Medical device maker Zimmer Biomet Holdings (NYSE:ZBH) raised its annual adjusted profit forecast on Thursday as it anticipates lower-than-expected tariff impacts, sending shares up 6% in morning trading. The Warsaw, Indiana-based company now expects about $40 million in tariff headwinds for 2025, down from its previous estimate of $60 million to $80 million. "Our tariff assumption is better than we originally expected, as we’ve had more time to work through our mitigation strategies and are seeing lower overall tariff rates," CFO Suketu Upadhyay told analysts in post-earnings conference call. The company previously expected tariff risks in China. Medical device makers have benefited from a surge in demand as more people, particularly older Americans, seek health care services and surgical procedures. Zimmer lifted its 2025 adjusted profit per share $8.10 to $8.30, up from its prior view of $7.90 to $8.10 per share. Analysts were expecting $7.97 per share, according to data compiled by LSEG. It posted an adjusted profit of $2.07 per share during the quarter ended June 30, topping estimates of $1.98 per share. Its second-quarter revenue came in at $2.08 billion, also above expectations of $2.05 billion. Zimmer said it expects 2025 revenue growth between 6.7% and 7.7%, from its prior 5.7% to 8.2% forecast. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks – 6 model portfolios fueled by AI stock picks with a stellar performance this year.. In 2024 alone, ProPicks' AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if ZBH is on your watchlist, it could be very wise to know whether or not it made the ProPicks lists.

Click Subscribe #ZimmerBiomet #MedicalDevices #ProfitForecast #StockMarket #Investing

Monogram Technologies to Be Acquired by Zimmer Biomet in Transformational Robotics Deal Shares of Monogram Technologies (MGRM) surged 100% in early trading following the announcement of a definitive agreement to be acquired by Zimmer Biomet (ZBH) i

#MonogramTechnologies #MGRM to be acquired by #zimmerbiomet in a game-changing robotics deal! The move signals major momentum in surgical innovation and orthopedic tech.
prismmarketview.com/monogram-tec...

Zimmer Biomet's Q1 earnings highlight strategic growth in the orthopedic sector. The company updates full-year 2025 adjusted earnings per share guidance to include Paragon 28, currency, and the impact from current tariff proposals. Read more at: buff.ly/VrgETVb #tmdmag #medtech #zimmerbiomet

Zimmer Biomet stock falls on lowered EPS guidance Investing.com -- Shares of Zimmer Biomet Holdings (NYSE:ZBH) tumbled 10% following the company’s updated earnings guidance that fell short of analyst expectations. Despite reporting first-quarter earnings that slightly beat estimates, the medical device maker revised its full-year 2025 earnings per share (EPS) forecast downward, citing the impact of its recent acquisition and potential tariffs. For the first quarter ended March 31, 2025, Zimmer Biomet reported net sales of $1.909 billion, marking a 1.1% increase from the previous year and a 2.3% rise on a constant currency basis. The company’s adjusted diluted EPS came in at $1.81, surpassing the consensus estimate of $1.77. However, investors were caught off guard by the company’s forward-looking guidance. Zimmer Biomet now expects its full-year 2025 EPS to be between $7.90 and $8.10, compared to the consensus projection of $8.21. The updated guidance incorporates the acquisition of Paragon 28, which closed on April 21, 2025, and the anticipated effects of current tariff proposals. Although the company anticipates reported revenue growth of 5.7% to 8.2% for the year, or 5.7% to 7.7% on a constant currency basis, the downward revision in EPS overshadowed the sales outlook. TD Cowen analyst Joshua Jennings commented on the results, stating, "The acquisition and tariffs drove a downward revision to EPS guidance." Jennings noted that Zimmer Biomet’s first-quarter sales outperformed estimates with ex-FX growth of 2.3%. However, the company’s U.S. Ortho growth lagged behind Stryker Corp. (NYSE:SYK), was competitive with Smith & Nephew (LON:SN) (SNN), and exceeded that of Johnson & Johnson (NYSE:JNJ). Despite the acquisition of Paragon 28, Zimmer Biomet maintains its organic growth expectations for the core business at 3.0% to 5.0% for the year. The company’s recent highlights include the completion of the Paragon 28 acquisition, which strengthens its position in the foot and ankle orthopedic segment, and the showcase of a broad portfolio of innovations at the American Academy of Orthopaedic Surgeons annual meeting. Furthermore, Zimmer Biomet received FDA clearance for a revision knee implant component and launched a campaign with Arnold Schwarzenegger to empower people with joint pain. Zimmer Biomet’s stock movement today reflects investor reaction to the company’s revised earnings outlook, highlighting the sensitivity of the market to future earnings potential, particularly in the face of acquisitions and macroeconomic factors such as tariffs. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #ZimmerBiomet #StockMarket #InvestmentNews #EPS #FinancialNews

Zimmer Biomet lowers 2025 profit forecast on acquisition costs, tariff uncertainty (Reuters) -Zimmer Biomet Holdings on Monday lowered its full-year adjusted profit forecast, as the medical device maker anticipates a hit from its recent acquisition of Paragon 28, currency volatility, and proposed tariffs. Investors and analysts are closely monitoring how medical device makers will handle any impact from the Trump administration’s tariffs and whether they expect benefits from foreign currency fluctuations. Earlier this year, Zimmer said that it would acquire medical device firm Paragon 28 for $1.1 billion, to expand its portfolio of orthopedic surgical devices. Zimmer expects 2025 adjusted profit per share in the range of $7.90 to $8.10, compared with its prior view of $8.15 to $8.35 per share. Analysts were expecting annual profit of $8.19 per share, according to data compiled by LSEG. The Warsaw, Indiana-based company expects currency swings to have a negligible to marginally positive effect on its 2025 revenue, revising its initial forecast of a 1.5% to 2% negative impact to a range of 0% to 0.5%. Last week, peer Stryker Corp (NYSE:SYK) reduced its 2025 profit outlook and said it anticipated a $200 million tariff impact in the year. However, Zimmer’s first-quarter profit and revenue both came in slightly above expectations, due to strong demand for its devices used in hip and knee procedures. Combined sales at Zimmer’s hips and knees units came in at $1.29 billion, compared to $1.28 billion, a year ago. Zimmer’s first-quarter revenue came in at $1.91 billion, slightly ahead of estimates of $1.90 billion. ZBH: A Bull or Bear Market Play? Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks – 6 model portfolios fueled by AI stock picks with a stellar performance this year.. In 2024 alone, ProPicks' AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if ZBH is on your watchlist, it could be very wise to know whether or not it made the ProPicks lists.

Click Subscribe #ZimmerBiomet #ProfitForecast #HealthcareStocks #AcquisitionCosts #TariffUncertainty

Zimmer Biomet announced a definitive agreement to Acquire Paragon 28. More on how the acquisition demonstrates Zimmer Biomet's commitment to investing in higher growth end-markets: buff.ly/xyYlbTj #tmdmag #medtech #manufacturing #zimmerbiomet #paragon28

SCOTUS Denies Petition Challenging Post-Patent Expiration Royalty Obligations Upheld in Arbitration Yesterday, the U.S. Supreme Court (SCOTUS) denied the petition for writ of certiorari filed in Zimmer Biomet Holdings, Inc. v. Insall, which challenged an arbitration award ordering Zimmer Biomet to continue...

🚨 SCOTUS denies Zimmer Biomet's petition, upholding arbitration that mandates ongoing royalty payments for knee replacement tech post-patent expiration. This decision reinforces the separation of royalties from patent rights.

#SCOTUS #ZimmerBiomet #Ar… https://ipwatchdog.com/2024/12/10/scotus-den…

Screenshot of article from Market Watch entitled “Two years after Ukraine invasion, the corporate fight against Russia continues.”

#StandWithUkraine
#YaleCELIList

“Two years after Ukraine invasion, the corporate fight against Russia continues.” (from #MarketWatch): www.marketwatch.com/story/two-ye...

#CarlsJr
#Cloudflare
#Fleetcor
#Guess
#HuntsmanCorp
#IQVIA
#Patreon
#RiotGames
#Sbarro
#TGIFridays
#Tupperware
#ZimmerBiomet